

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (original) Compounds of formula (I)

cyclo [NX<sub>1</sub>-R<sub>1</sub>-CO-NX<sub>2</sub>-R<sub>2</sub>-CO-NX<sub>3</sub>-R<sub>3</sub>-CO-NX<sub>4</sub>-R<sub>4</sub>-CO-NX<sub>5</sub>-R<sub>5</sub>-CO]

where: R<sub>1</sub> is selected from:

CH(CH<sub>2</sub>)<sub>3</sub>NHC(NH)NH<sub>2</sub>; C[CH<sub>n</sub>F<sub>m</sub>](CH<sub>2</sub>)<sub>3</sub>NHC(NH)NH<sub>2</sub>

R<sub>2</sub> is the group CH<sub>2</sub>; CH<sub>2</sub>-CH<sub>2</sub>;




R<sub>3</sub> is selected from CHCH<sub>2</sub>COOH; C[CH<sub>n</sub>F<sub>m</sub>]CH<sub>2</sub>-COOH;

R<sub>4</sub> is selected from CH-CH<sub>2</sub>-Ph; C[CH<sub>n</sub>F<sub>m</sub>]CH<sub>2</sub>-Ph; CH-CH<sub>2</sub>-(4-OH)Ph;

CH-CH<sub>2</sub>-(4-OMe)Ph; CH-CH<sub>2</sub>-(4-F)Ph; CH-CH(OH)-Ph; C(CH<sub>3</sub>)<sub>2</sub>; CH-C(CH<sub>3</sub>)<sub>3</sub>;

CH-CH<sub>2</sub>-COOH;



R<sub>5</sub> is selected from CH-CH<sub>2</sub>-Ph; C[CH<sub>n</sub>F<sub>m</sub>]CH<sub>2</sub>-Ph; CH-CH(CH<sub>3</sub>)<sub>2</sub>; C[CH<sub>n</sub>F<sub>m</sub>]CH

(CH<sub>3</sub>)<sub>2</sub>; CH-C(CH<sub>3</sub>)<sub>3</sub>;

or, the group NX<sub>4</sub>-R<sub>4</sub>-CO-NX<sub>5</sub>-R<sub>5</sub>-CO is 3-aminomethyl-benzoyl N + M = 3

$X_1-X_5$ , which may be the same or different, are H,  $(CH_2)_n-CH_3$ ;



$(CH_2)_n-CHF_2$ ;  $(CH_2)_n-CH_2F$ ,  $(CH_2)_n-CF_3$  where  $n = 0-3$ ;

with the proviso that there is at least one  $\alpha$ -fluoroalkylated amino acid present in the formula (I) compound;

where each  $NX-R-CO$  amino acid can have an absolute type R or type S configuration; their individual enantiomers, diastereoisomers, the related mixtures, the pharmaceutically acceptable salts.

2. (original) Compound according to claim 1, selected from the group consisting of :

- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-Tfm-Phe);
- c (Arg-Gly-Asp-D-Phe-(*R*, *S*)-Dfm-Phe);
- c (Arg-Gly-Asp-(*R* or *S*)-Tfm-Phe-Asp-D-Phe-Val);
- c (Arg-Gly-Asp-(*R* or *S*)-Tfm-Phe-Val);
- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-Tfm-Val)
- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-N-Me-Tfm-Phe).

3.(currently amended) Use of the compounds according to ~~claims 1 or 2~~ claim 1 as medicaments.

4. (currently amended) Use of the compounds according to ~~claims 1 or 2~~ claim 1 for the preparation of medicaments that inhibit the receptors belonging to the family of the integrins belonging to the  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  system.

5. (original) Use according to claim 4, where said medicaments have antiangiogenic activity.

6. (original) Use according to claim 5, where said medicaments have antimetastatic activity.

7. (original) Use according to claim 5, where said medicaments are useful for the treatment of a disease selected from the group consisting of retinopathy, acute kidney failure, and osteoporosis.

8. (currently amended) Pharmaceutical compositions containing at least one compound according to ~~claims 1 or 2~~ claim 1 as an active ingredient in a mixture with pharmaceutically acceptable vehicles and/or excipients.

**DAL POZZO**  
**U.S. National Phase of PCT/IT2003/000446**

9. (currently amended) Use of compounds according to ~~claims 1-2~~ claim 1 for the preparation of diagnostic agents.

10. (original) Use according to claim 9, where said compound is labelled.

11. (currently amended) Use according to ~~claims 9 or 10~~ claim 9, where said diagnostic agent is used for the detection and location of tumour masses.

12. (original) Use according to claim 11, where said tumour masses are small.

13. (currently amended) Use according to ~~claims 9 or 10~~ claim 9, where said diagnostic agent is used for detecting and locating arterial occlusion events.

14. (original) Use according to claim 13, where said event is a stroke or myocardial infarct.

15. (currently amended) A diagnostic agent containing at least one compound according to ~~claims 1 or 2~~ claim 1.